Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Proprietary Name Review Letter - Wilate, November 9, 2009

Our STN:  125251/0                                                                          

Octapharma Pharmazeutika Produktionsges.m.b.H.
Attention:  Mr. Stanley Ammons
Octapharma USA, Inc.
121 River Street, 12th floor
Hoboken, NJ  07030

Dear Mr. Ammons:

We have reviewed your submission dated May 10, 2007, to your biologics license application (BLA) for Coagulation Factor VIII/von Willebrand Factor Complex (Human) requesting a proprietary name review. 

In consultation with CBER’s Advertising and Promotional Labeling Branch (APLB), we conclude that under the Federal Food, Drug, and Cosmetic Act and applicable regulations, your proposed proprietary name, Wilate, is acceptable at this time.

If you have any questions, please contact Pauline Cottrell at (301) 827-6162.

Sincerely yours,


Basil Golding, M.D.
Division of Hematology
Office of Blood Research and Review
Center for Biologics
Evaluation and Research

Page Last Updated: 05/25/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English